NNOX vs. CDRE, LQDA, INMD, BLFS, RXST, AORT, MDXG, PLSE, FNA, and ESTA
Should you be buying Nano-X Imaging stock or one of its competitors? The main competitors of Nano-X Imaging include Cadre (CDRE), Liquidia (LQDA), InMode (INMD), BioLife Solutions (BLFS), RxSight (RXST), Artivion (AORT), MiMedx Group (MDXG), Pulse Biosciences (PLSE), Paragon 28 (FNA), and Establishment Labs (ESTA). These companies are all part of the "medical equipment" industry.
Nano-X Imaging vs.
Nano-X Imaging (NASDAQ:NNOX) and Cadre (NYSE:CDRE) are both small-cap business services companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation.
Cadre has a net margin of 6.34% compared to Nano-X Imaging's net margin of -465.38%. Cadre's return on equity of 12.88% beat Nano-X Imaging's return on equity.
Nano-X Imaging received 15 more outperform votes than Cadre when rated by MarketBeat users. Likewise, 72.09% of users gave Nano-X Imaging an outperform vote while only 55.17% of users gave Cadre an outperform vote.
Nano-X Imaging currently has a consensus price target of $17.50, indicating a potential upside of 206.48%. Cadre has a consensus price target of $39.67, indicating a potential upside of 22.35%. Given Nano-X Imaging's stronger consensus rating and higher possible upside, research analysts plainly believe Nano-X Imaging is more favorable than Cadre.
Cadre has higher revenue and earnings than Nano-X Imaging. Nano-X Imaging is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.
In the previous week, Nano-X Imaging had 7 more articles in the media than Cadre. MarketBeat recorded 9 mentions for Nano-X Imaging and 2 mentions for Cadre. Nano-X Imaging's average media sentiment score of 0.47 beat Cadre's score of 0.00 indicating that Nano-X Imaging is being referred to more favorably in the media.
Nano-X Imaging has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500. Comparatively, Cadre has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.
21.5% of Nano-X Imaging shares are owned by institutional investors. Comparatively, 44.0% of Cadre shares are owned by institutional investors. 7.7% of Nano-X Imaging shares are owned by insiders. Comparatively, 37.0% of Cadre shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Cadre beats Nano-X Imaging on 9 of the 17 factors compared between the two stocks.
Get Nano-X Imaging News Delivered to You Automatically
Sign up to receive the latest news and ratings for NNOX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nano-X Imaging Competitors List
Related Companies and Tools
This page (NASDAQ:NNOX) was last updated on 3/4/2025 by MarketBeat.com Staff
